A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
Public ClinicalTrials.gov record NCT04121221. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to Placebo
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks
Study identification
- NCT ID
- NCT04121221
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,016 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 19, 2019 (Actual)
- Primary completion
- Jun 13, 2023 (Actual)
- Completion
- Jun 13, 2023 (Actual)
- Last update posted
- Aug 5, 2026
2019 – 2023
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mapi Pharma Research site 08 | Birmingham | Alabama | 35209 | — |
| Mapi Pharma Research site 11 | Cullman | Alabama | 35058 | — |
| Mapi Pharma Research site 15 | Pasadena | California | 91105 | — |
| Mapi Pharma Research site 14 | Denver | Colorado | 80209 | — |
| Mapi Pharma Research site 12 | Washington D.C. | District of Columbia | 20007 | — |
| Mapi Pharma Research site 17 | Homestead | Florida | 33032 | — |
| Mapi Pharma Research site 09 | Miami | Florida | 33136 | — |
| Mapi Pharma Research site 01 | Northbrook | Illinois | 60062 | — |
| Mapi Pharma Research site 02 | Detroit | Michigan | 48201 | — |
| Mapi Pharma Research site 13 | Westerville | Ohio | 43081 | — |
| Mapi Pharma Research site 04 | Round Rock | Texas | 78681 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 101 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04121221, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04121221 live on ClinicalTrials.gov.